Next Article in Journal
Alternatives to Subcutaneous Immunotherapy for Allergic Rhinitis
Previous Article in Journal / Special Issue
Could Modifying the Skin Microbiome, Diet, and Lifestyle Help with the Adverse Skin Effects after Stopping Long-Term Topical Steroid Use?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Allergies
Volume 2
Issue 1
10.3390/allergies2010002
Review Report
allergies-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Itchy Toxicodendron Plant Dermatitis

Allergies 2022, 2(1), 16-22; https://doi.org/10.3390/allergies2010002
by Angelina Labib and Gil Yosipovitch *
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Allergies 2022, 2(1), 16-22; https://doi.org/10.3390/allergies2010002
Submission received: 22 July 2021 / Revised: 25 October 2021 / Accepted: 12 January 2022 / Published: 19 January 2022
(This article belongs to the Special Issue Allergies Specifically Dedicated to Allergic Contact Dermatitis)

Round 1

Reviewer 1 Report

The manuscript by Labib and Yosipovitch provides a state of the art overview about new research, experimental therapies and the therapeutic standards for treatment of toxicodendron plant dermatitis, including poison ivy contact dermatitis. This is almost a neglected disease, with millions of sensitized individuals in the United States, Japan and other countries where these plants are endemic. This review comes at the right time where global warming and increasing air CO2 levels have led to increased growth and spread of poison ivy and related plants world-wide.

The review is comprehensive, with no major omissions, providing valuable insights for dermatologists and scientists into the most recent research on allergic and inflammatory mechanisms elicited by urushiol, the major poison ivy allergen. While a standard oral steroid treatment course has been shown to provide relief and resolution for exposed patients, treatment has to be given early to be effective, and many practitioners remain poorly educated about this intervention. The authors summarize recent rodent studies identifying novel inflammatory and pruritic pathways involving Interleukin 33, TSLP and other mediators.

One new effort the authors omitted is the development an immunization against poison ivy sensitization, currently in for clinical trials. This vaccine is developed by the company, Hapten Sciences:

 

https://news.olemiss.edu/hapten-sciences-begin-clinical-trials-poison-ivy-vaccine/

https://clinicaltrials.gov/ct2/show/NCT04853823

https://www.haptensciences.com/products

https://pubmed.ncbi.nlm.nih.gov/31045932/

https://www.haptensciences.com/images/hapten.pdf

https://patents.google.com/patent/US9408822B2/en

It would be helpful if the authors could describe and comment on this new development for this review. This would be a valuable addition to this manuscript.

 

 

 

Author Response

Thank you very much for your time to respond to this review and thank you for the positive comments. I have included a section in the "Treatment" section regarding a previous animal model and the current clinical trial regarding a vaccine for urushiol exposure. 

Reviewer 2 Report

Nice and interesting review on a common contact allergen in the US

Author Response

Thank you very much for your time to respond to this review and thank you for the positive comments.

Round 2

Reviewer 1 Report

I thank the authors for addressing all my comments satisfactorily. The manuscript is very much improved. 

Back to TopTop